阿托伐他汀强化治疗对急性冠脉综合征BNP及血脂的早期影响
|
摘要
目的：
探讨阿托伐他汀强化治疗短期(5天)内对急性冠脉综合征(ACS)患者血浆B型钠尿肽(B-type natriuretic peptide或称脑钠肽brain natriuretic peptide,BNP)及血脂水平的影响。
对象和方法：
本研究为随机单盲、对照研究。选取46例ACS患者,于入院24小时内均予以常规治疗(包括溶栓剂、抗凝剂、ACEI、p受体阻滞剂、钙通道拮抗剂、硝酸酯类等)并随机分为两组：常规治疗组(阿托伐他汀20mg,一次／晚)、强化治疗组(阿托伐他汀40mg,一次／晚),分别治疗前及治疗5天后检测患者血浆BNP、血脂水平。另选取正常体检者23例为对照组。
结果：
1)、常规治疗组与强化治疗组ACS患者入院治疗前的血脂TC、TG、HDL及LDL-C水平无差别(P>0.05),具有可比性。治疗5天后两组患者TC、TG、HDL及LDL-C无明显改变(P>0.05)。
2)、常规治疗组与强化治疗组患者治疗前血浆BNP水平无明显差别(P>0.05),但均较对照组明显增高(P=0.000)。治疗5天后,常规治疗组血浆BNP由683.23±199.56pg／ml降至574.56±194.08pg／ml(P=0.001),强化治疗组由674.24±173.55 pg／ml降至420.31±141.93 pg／ml(P=0.000)。
3)、强化治疗组BNP下降水平与常规治疗组更为显著,两组比较有统计学意义(P<0.01)。
结论：
1、ACS患者BNP水平显著高于对照组人群,表明ACS急性发病期存在心功能障碍。
2、阿托伐他汀强化及常规短期治疗对ACS患者均能降低血浆BNP水平,而对其血脂水平前后无显著性影响。说明其降脂作用在短期内尚未显现,且其改善心功能标志物血浆BNP作用独立于降脂作用。
3、大剂量阿托伐他汀强化治疗组的血浆BNP下降水平较常规剂量组更为显著,表明其降低BNP的作用可能与剂量有关。
4、对ACS患者阿托伐他汀强化治疗与常规治疗短期治疗安全性相似。
Objectives:
To observe the early effects(5 days) on BNP(B-type natriuretic peptide/brain natriuretic peptide) and serum lipids by atorvastatin intensive treatment in patients with acute coronary syndrome(ACS).
Subjects & Methods:
Forty-six patients with ACS admitted in the Dept. Cardiology, Xiangya hospital from Sept.2008 to Feb.2009, diagnosed by clinical symptoms, electrocardiogram, myocardial enzymes, troponin I, coronary angiography & other inspections, were enrolled in this study. All patients were given conventional treatments (including thrombolytic agents, anticoagulant, ACEI,calcium channel antagonists and nitrate, etc) within 24 hours after being hospitalized, and then divided randomly into two groups:conventional therapy group (atorvastatin 20mg QN) and the enhanced treatment group (atorvastatin 40mg QN). Before and after five days treatment, the levels of plasma BNP and lipids were detected. In addition,23 patients acted as control group, whose relevant examination results including blood biochemistry, myocardial enzymes, ECG, echocardiography and coronarography were normal.
Results:
1). The levels of plasma TC, TG, LDL, HDL showed no significant difference between the conventional therapy group and the enhanced treatment group before treatment (P>0.05).At five days after treatment, the TC, TG, LDL were decreased and the HDL increased in the both groups. But the difference between before and after treatment in the both groups had no statistical significance (P>0.05)
2). There was no difference in plasma BNP level between the conventional therapy group and the enhanced treatment group before the treatment (P>0.05), but dramatically much higher than control group (P=0.000). After 5 days'treatment, the BNP levels was decreased from 683.23±199.56 pg/ml to 574.56±194.08 pg/ml (p=0.001) in the conventional therapy group, and from 674.24±173.55 pg/ml to 420.31±141.93 pg/ml (P=0.000) in the enhanced treatment group.
3). The plasma BNP level in the enhanced treatment group was decreased significantly compared with that in the conventional therapy group (P<0.01).
Conclusions:
1). The plasma BNP level in the patients with ACS was much higher than healthy persons, which suggested that the patients with ACS were associated with heart dysfunction.
2). The atorvastatin enhanced and regular treatment for five days could obviously reduce the level of plasma BNP, while the plasma levels of TC, TG, HDL and LDL-C were changed without significance. The findings indicated the heart function improvement by atorvastatin was independent on lowering lipids.
3). The decline of the level of plasma BNP in the atorvastatin enhanced treatment group was more obvious than that in the regular treatment group, which suggested the efficiency was possibly dose dependent.
4). The safety was similar between enhanced treatment group and regular conventional therapy group for short period in patients with ACS.
探讨阿托伐他汀强化治疗短期(5天)内对急性冠脉综合征(ACS)患者血浆B型钠尿肽(B-type natriuretic peptide或称脑钠肽brain natriuretic peptide,BNP)及血脂水平的影响。
对象和方法：
本研究为随机单盲、对照研究。选取46例ACS患者,于入院24小时内均予以常规治疗(包括溶栓剂、抗凝剂、ACEI、p受体阻滞剂、钙通道拮抗剂、硝酸酯类等)并随机分为两组：常规治疗组(阿托伐他汀20mg,一次／晚)、强化治疗组(阿托伐他汀40mg,一次／晚),分别治疗前及治疗5天后检测患者血浆BNP、血脂水平。另选取正常体检者23例为对照组。
结果：
1)、常规治疗组与强化治疗组ACS患者入院治疗前的血脂TC、TG、HDL及LDL-C水平无差别(P>0.05),具有可比性。治疗5天后两组患者TC、TG、HDL及LDL-C无明显改变(P>0.05)。
2)、常规治疗组与强化治疗组患者治疗前血浆BNP水平无明显差别(P>0.05),但均较对照组明显增高(P=0.000)。治疗5天后,常规治疗组血浆BNP由683.23±199.56pg／ml降至574.56±194.08pg／ml(P=0.001),强化治疗组由674.24±173.55 pg／ml降至420.31±141.93 pg／ml(P=0.000)。
3)、强化治疗组BNP下降水平与常规治疗组更为显著,两组比较有统计学意义(P<0.01)。
结论：
1、ACS患者BNP水平显著高于对照组人群,表明ACS急性发病期存在心功能障碍。
2、阿托伐他汀强化及常规短期治疗对ACS患者均能降低血浆BNP水平,而对其血脂水平前后无显著性影响。说明其降脂作用在短期内尚未显现,且其改善心功能标志物血浆BNP作用独立于降脂作用。
3、大剂量阿托伐他汀强化治疗组的血浆BNP下降水平较常规剂量组更为显著,表明其降低BNP的作用可能与剂量有关。
4、对ACS患者阿托伐他汀强化治疗与常规治疗短期治疗安全性相似。
Objectives:
To observe the early effects(5 days) on BNP(B-type natriuretic peptide/brain natriuretic peptide) and serum lipids by atorvastatin intensive treatment in patients with acute coronary syndrome(ACS).
Subjects & Methods:
Forty-six patients with ACS admitted in the Dept. Cardiology, Xiangya hospital from Sept.2008 to Feb.2009, diagnosed by clinical symptoms, electrocardiogram, myocardial enzymes, troponin I, coronary angiography & other inspections, were enrolled in this study. All patients were given conventional treatments (including thrombolytic agents, anticoagulant, ACEI,calcium channel antagonists and nitrate, etc) within 24 hours after being hospitalized, and then divided randomly into two groups:conventional therapy group (atorvastatin 20mg QN) and the enhanced treatment group (atorvastatin 40mg QN). Before and after five days treatment, the levels of plasma BNP and lipids were detected. In addition,23 patients acted as control group, whose relevant examination results including blood biochemistry, myocardial enzymes, ECG, echocardiography and coronarography were normal.
Results:
1). The levels of plasma TC, TG, LDL, HDL showed no significant difference between the conventional therapy group and the enhanced treatment group before treatment (P>0.05).At five days after treatment, the TC, TG, LDL were decreased and the HDL increased in the both groups. But the difference between before and after treatment in the both groups had no statistical significance (P>0.05)
2). There was no difference in plasma BNP level between the conventional therapy group and the enhanced treatment group before the treatment (P>0.05), but dramatically much higher than control group (P=0.000). After 5 days'treatment, the BNP levels was decreased from 683.23±199.56 pg/ml to 574.56±194.08 pg/ml (p=0.001) in the conventional therapy group, and from 674.24±173.55 pg/ml to 420.31±141.93 pg/ml (P=0.000) in the enhanced treatment group.
3). The plasma BNP level in the enhanced treatment group was decreased significantly compared with that in the conventional therapy group (P<0.01).
Conclusions:
1). The plasma BNP level in the patients with ACS was much higher than healthy persons, which suggested that the patients with ACS were associated with heart dysfunction.
2). The atorvastatin enhanced and regular treatment for five days could obviously reduce the level of plasma BNP, while the plasma levels of TC, TG, HDL and LDL-C were changed without significance. The findings indicated the heart function improvement by atorvastatin was independent on lowering lipids.
3). The decline of the level of plasma BNP in the atorvastatin enhanced treatment group was more obvious than that in the regular treatment group, which suggested the efficiency was possibly dose dependent.
4). The safety was similar between enhanced treatment group and regular conventional therapy group for short period in patients with ACS.
引文
[1]陆再英,钟南山.内科学.第七版.北京：人民卫生出版社,2008：274.
[2]Kristen J. Overbaugh. Acute coronary syndrome. AJN.2009,109(5):42-52.
[3]Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005,352(16):1685-95.
[4]Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation, 2002 Mar,105:1135-1143.
[5]American Heart Association:2004. Heart and Stroke Statistical Update.
[6]孔灵芝,胡盛寿.中国心血管病报告2006.北京：中国大百科全书出版社,2008：36-38,69-70.
[7]美国心脏学院(ACC)／美国心脏病学会(AHA),欧洲心脏病学会(ESC).2000年ACC／AHA／HE不稳定心绞痛／非ST抬高心肌梗死指南(一).现代实用医学,2002；14(1)：51-5.
[8]Michael Weber, Christian Hamm. Role of B-type natriuretic peptide(BNP) and NT-proBNP in clinical routine. Heart,2006;92:843-849.
[9]Valentina Loria, Milena Leo, Gina Biasillo,et al. Biomarkers in Acute Coronary Syndrome. Biomarker Insights,2008(3):453-468.
[10]Christopher Heeschen, Christian W. Hamm, Veselin Mitrovic,et al. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Dynamic Risk Stratification of Patients With Acute Coronary Syndromes. Circulation.2004,110:3206-3212.
[11]袁龙,郝文君.脑利钠肽在急性冠脉综合征临床应用的研究进展.中国实用内科杂志,2007,27(12)：979-981.
[12]王鸿珍,何汝敏,曹久妹等.BNP对急性心肌梗死再灌注治疗效果的评价国际心血管病杂志,2007,34(5)：378-380.
[13]Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention:results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol.2007 Mar 27;49(12):1272-8.
[14]Timo Lenderink, Eric Boersma, Anselm K. Gitt, et al. Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users:a report from the first Euro Heart Survey on acute coronary syndromes. European Heart Journal.2006,27: 1799-1804.
[15]Shinya Okazaki, Takayuki Yokoyama,Katsumi Miyauchi, et al. Early Statin Treatment in Patients With Acute Coronary Syndrome:Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event:The ESTABLISH Study. Circulation 2004;110;1061-1068.
[16]Helen YL, Catherine EC, Teisha AR. Use of Secondary Prevention Drug Therapy in Patients With Acute Coronary Syndrome After Hospital Discharge. Journal of Managed Care Pharmacy.2008;14(3):271-280.
[17]张平,李颖莉,秦勤.他汀类药物在急性冠脉在急性冠脉综合征中的应用及其进展.中国分子心脏病学杂志.2007,34：170-176.
[18]Gresser U, Gathof BS.Atorvastatin:gold standard for prophylaxis of myocardial ischemia and stroke-comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. Eur J Med Res.2004 Jan 26;9(1):1-17.
[19]Scott K, Gregory G, Anders G, et al. High-Dose Atorvastatin Enhances the Decline inInflammatory Markers in Patients with Acute Coronary Syndromes in the MIRACL Study. Circulation.2003;108:1560-1566.
[20]Palazzuoli Alberto, Iovine Francesca, Scali Chiara,et al. Acute Coronary Syndromes:From The Laboratory Markers To The Coronary Vessels. Biomarker Insights.2006,1:123-130.
[21]林涛,马依彤.心脏标志物在急性冠脉综合征中的应用进展.心血管病学进展.2008,29(4)：594-597.
[22]Baxer GF. Natriuretic peptides and myocardial ischaemia. Basic Res Cardiol, 2004,99(2):90-93.
[23]de Lemos, J.A., Morrow, D.A. and Bentley, J.H. et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med.,2001,345:1014-1021.
[24]Omland, T., Persson, A., Ng, L., O'Brien, R., Karlsson, T. and Herlitz, J. Hartford N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation,2002,106:2913-8.
[25]Morrow, D.A., de Lemos, J., Sabatine, M., Murphy, S.A. and Demopoulos, L.A. et al. evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non ST-elevation myocardial infarction. J. Am. Coll. Cardiol., 2003.41:1264-127.
[26]Trygve Brugger-Andersen, Volker Ponitz, et al. B-type natriuretic peptide is a long-term predictor of all-cause mortality, whereas high-sensitive C-reactive protein predicts recurrent short-term troponin T positive cardiac events in chest pain patients:a prognostic study. BMC Cardiovascular Disorders 2008,8:34.
[27]M. Christ, A. Thuerlimann, K. Laule, et al. Long-term prognostic value of B-type natriuretic peptide in cardiac and non-cardiac causes of acute dyspnoea. Eur J Clin Invest.2007,37(11):834-41.
[28]赵瑞英,韦铁民,曾春来,等.急性心肌梗死患者B型钠尿肽的变化.中国动脉硬化杂志.2005,13(2)：223-224.
[29]王玉玲,买苏木,杨建中.急性冠脉综合征患者BNP浓度及临床意义.中国热带医学.2008年,8(10)：1742-1743.
[30]张代民,刘志华.他汀类药物在治疗心血管疾病中的多重效应.国际心血管病杂志.2008,35(1)：42-45.
[31]秦晋梅,李建军.他汀类药物的抗炎作用.中国动脉硬化杂志.2004,12(3)：363-366.
[32]杨长卫,郭飞,孟兆兵等.急性冠脉综合征早期他汀类药物对血管内皮功能的保护作用.心血管病学进展.2008,29：24-29.
[33]Packard CJ, O Reilly DS, Caslake MJ, et al. B-type natriuretic peptide protein expression in the natural progression of human coronary atherosclerosis Arterioscler Thromb Vasc Biol,2006,26 (11):2523-2529.
[34]Gresser U, Gathof BS.Atorvastatin:gold standard for prophylaxis of myocardial ischemia and stroke-comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.Eur J Med Res.2004 Jan 26;9(1):1-17.
[35]郑欢,罗明.炎性细胞因子与急性心肌梗死后心室重构的关系.心血管病学进展.2007,28(2)：208-211.
[36]Manabu Kashiwagi, Atsushi Tanaka, Hironori Kitabata, et al. Relationship Between Coronary Arterial Remodeling, Fibrous Cap Thickness and High-Sensitivity C-Reactive Protein Levels in Patients With Acute Coronary Syndrome. Circ J.2009,73:1291-1295.
[37]Bonnet J, McPherson R, Tedgui A,et al. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease:results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther.2008 Dec;30(12):2298-313.
[1]孔灵芝,胡盛寿.中国心血管病报告2006[M].北京：中国大百科全书出版社,2008：69-70.
[2]Rosamond W, Flegal K, Friday G, et al. Heart Disease and Stroke Statistics—2007 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation.2007;达式 115(5):69-171.
[3]Helen Y. L. Catherine E. C. Teisha A. R. Use of Secondary Prevention Drug Therapy in Patients With Acute Coronary Syndrome After Hospital Discharge. J Manag Care Pharm.2008;14(3):271-80.
[4]张代民,刘志华.他汀类药物在治疗心血管疾病中的多重效应.国际心血管病杂志.2008,35(1)：42-45.
[5]秦晋梅,李建军.他汀类药物的抗炎作用.中国动脉硬化杂志.2004,12(3)：363-366.
[6]杨长卫,郭飞,孟兆兵等.急性冠脉综合征早期他汀类药物对血管内皮功能的保护作用.心血管病学进展.2008,29：24-29.
[7]Gresser U, Gathof BS.Atorvastatin:gold standard for prophylaxis of myocardial ischemia and stroke-comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.Eur J Med Res.2004 Jan 26;9(1):1-17.
[8]Ray KK, Cannon CP, McCabe CH,et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes:results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol.2005 Oct 18;46(8):1405-10.
[9]Ray KK, Cannon CP. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol.2004 Dec;15(6):637-43.
[10]Fraley AE, Schwartz GG, Olsson AG et al. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes:Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering)trial.J Am Coll Cardiol.2009 Jun 9;53(23):2186-96.
[11]Ray KK, Cannon CP, Cairns R,et al. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes:results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol.2009 Mar;29(3):424-30.
[12]Schoenhagen P, Tuzcu EM, Apperson-Hansen C,et al. Determinants of arterial wall remodeling during lipid-lowering therapy:serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation.2006 Jun 20; 113(24): 2826-34.
[13]Bonnet J, McPherson R, Tedgui A,et al. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease:results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther.2008 Dec;30(12):2298-313.
[14]Lewandowski M, Kornacewicz-Jach Z, Millo B,et al. The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value. Cardiol J.2008;15(4):357-64.
[15]Kanadasi M, Cayli M, Demirtas M et al. The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol. Heart Vessels.2006 Sep;21(5):291-7. Epub 2006 Sep 29.
[16]Stefanadis C, Toutouzas K, Tsiamis E, Relation between local temperature and C-reactive protein levels in patients with coronary artery disease:effects of atorvastatin treatment. Atherosclerosis.2007 Jun;192(2):396-400.
[17]王岚峰,吴双,关秀茹,等.脑钠素与急性心肌梗死预后关系的临床研究[J].中华心血管病杂志,2005,33：234-237.
[18]张华,王泰蓉,陈华,等.三种标志物联合检测在急性冠脉综合征的应用.标记免疫分析与临床.2006,13(4)：198-200.
[19]程翔,廖玉华,郑金娥等.不稳定心绞痛患者CD4+CD25+调节性T细胞检测及意义.中国分子心脏病学杂志.2006,6(1)：17-19.
[20]Hu Z, Li D, Hu Y, Yang K. Changes of CD4+CD25+ regulatory T cells in patients with acute coronary syndrome and the effects of atorvastatin. J Huazhong Univ Sci Technolog Med Sci.2007 Oct,27(5):524-7.
[21]Barderas MG, Tunon J, Darde VM, et al. Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome.Proteomics.2009 Apr;9(7):1982-93.
[22]费瑜,张文琪等.急性心肌梗死患者PTCA后血浆可溶性细胞黏附分子-1变化及阿托伐他汀对其影响.中国急救医学.2003,23(11)：806.
[23]李泽林,孙华保,宁丹霞,等.大剂量阿托伐他汀对急性冠状动脉综合征患者血清抗氧化能力的影响.中国动脉硬化杂志.2006,14(8)：701-704.
[24]林毅,陈新民,罗助荣,等.不同剂量阿托伐他汀对急性冠脉综合征患者炎症及血小板和纤溶活性的影响.中国全科医学.2007,10(13)：1060-1062.
[2]Kristen J. Overbaugh. Acute coronary syndrome. AJN.2009,109(5):42-52.
[3]Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005,352(16):1685-95.
[4]Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation, 2002 Mar,105:1135-1143.
[5]American Heart Association:2004. Heart and Stroke Statistical Update.
[6]孔灵芝,胡盛寿.中国心血管病报告2006.北京：中国大百科全书出版社,2008：36-38,69-70.
[7]美国心脏学院(ACC)／美国心脏病学会(AHA),欧洲心脏病学会(ESC).2000年ACC／AHA／HE不稳定心绞痛／非ST抬高心肌梗死指南(一).现代实用医学,2002；14(1)：51-5.
[8]Michael Weber, Christian Hamm. Role of B-type natriuretic peptide(BNP) and NT-proBNP in clinical routine. Heart,2006;92:843-849.
[9]Valentina Loria, Milena Leo, Gina Biasillo,et al. Biomarkers in Acute Coronary Syndrome. Biomarker Insights,2008(3):453-468.
[10]Christopher Heeschen, Christian W. Hamm, Veselin Mitrovic,et al. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Dynamic Risk Stratification of Patients With Acute Coronary Syndromes. Circulation.2004,110:3206-3212.
[11]袁龙,郝文君.脑利钠肽在急性冠脉综合征临床应用的研究进展.中国实用内科杂志,2007,27(12)：979-981.
[12]王鸿珍,何汝敏,曹久妹等.BNP对急性心肌梗死再灌注治疗效果的评价国际心血管病杂志,2007,34(5)：378-380.
[13]Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention:results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol.2007 Mar 27;49(12):1272-8.
[14]Timo Lenderink, Eric Boersma, Anselm K. Gitt, et al. Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users:a report from the first Euro Heart Survey on acute coronary syndromes. European Heart Journal.2006,27: 1799-1804.
[15]Shinya Okazaki, Takayuki Yokoyama,Katsumi Miyauchi, et al. Early Statin Treatment in Patients With Acute Coronary Syndrome:Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event:The ESTABLISH Study. Circulation 2004;110;1061-1068.
[16]Helen YL, Catherine EC, Teisha AR. Use of Secondary Prevention Drug Therapy in Patients With Acute Coronary Syndrome After Hospital Discharge. Journal of Managed Care Pharmacy.2008;14(3):271-280.
[17]张平,李颖莉,秦勤.他汀类药物在急性冠脉在急性冠脉综合征中的应用及其进展.中国分子心脏病学杂志.2007,34：170-176.
[18]Gresser U, Gathof BS.Atorvastatin:gold standard for prophylaxis of myocardial ischemia and stroke-comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. Eur J Med Res.2004 Jan 26;9(1):1-17.
[19]Scott K, Gregory G, Anders G, et al. High-Dose Atorvastatin Enhances the Decline inInflammatory Markers in Patients with Acute Coronary Syndromes in the MIRACL Study. Circulation.2003;108:1560-1566.
[20]Palazzuoli Alberto, Iovine Francesca, Scali Chiara,et al. Acute Coronary Syndromes:From The Laboratory Markers To The Coronary Vessels. Biomarker Insights.2006,1:123-130.
[21]林涛,马依彤.心脏标志物在急性冠脉综合征中的应用进展.心血管病学进展.2008,29(4)：594-597.
[22]Baxer GF. Natriuretic peptides and myocardial ischaemia. Basic Res Cardiol, 2004,99(2):90-93.
[23]de Lemos, J.A., Morrow, D.A. and Bentley, J.H. et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med.,2001,345:1014-1021.
[24]Omland, T., Persson, A., Ng, L., O'Brien, R., Karlsson, T. and Herlitz, J. Hartford N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation,2002,106:2913-8.
[25]Morrow, D.A., de Lemos, J., Sabatine, M., Murphy, S.A. and Demopoulos, L.A. et al. evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non ST-elevation myocardial infarction. J. Am. Coll. Cardiol., 2003.41:1264-127.
[26]Trygve Brugger-Andersen, Volker Ponitz, et al. B-type natriuretic peptide is a long-term predictor of all-cause mortality, whereas high-sensitive C-reactive protein predicts recurrent short-term troponin T positive cardiac events in chest pain patients:a prognostic study. BMC Cardiovascular Disorders 2008,8:34.
[27]M. Christ, A. Thuerlimann, K. Laule, et al. Long-term prognostic value of B-type natriuretic peptide in cardiac and non-cardiac causes of acute dyspnoea. Eur J Clin Invest.2007,37(11):834-41.
[28]赵瑞英,韦铁民,曾春来,等.急性心肌梗死患者B型钠尿肽的变化.中国动脉硬化杂志.2005,13(2)：223-224.
[29]王玉玲,买苏木,杨建中.急性冠脉综合征患者BNP浓度及临床意义.中国热带医学.2008年,8(10)：1742-1743.
[30]张代民,刘志华.他汀类药物在治疗心血管疾病中的多重效应.国际心血管病杂志.2008,35(1)：42-45.
[31]秦晋梅,李建军.他汀类药物的抗炎作用.中国动脉硬化杂志.2004,12(3)：363-366.
[32]杨长卫,郭飞,孟兆兵等.急性冠脉综合征早期他汀类药物对血管内皮功能的保护作用.心血管病学进展.2008,29：24-29.
[33]Packard CJ, O Reilly DS, Caslake MJ, et al. B-type natriuretic peptide protein expression in the natural progression of human coronary atherosclerosis Arterioscler Thromb Vasc Biol,2006,26 (11):2523-2529.
[34]Gresser U, Gathof BS.Atorvastatin:gold standard for prophylaxis of myocardial ischemia and stroke-comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.Eur J Med Res.2004 Jan 26;9(1):1-17.
[35]郑欢,罗明.炎性细胞因子与急性心肌梗死后心室重构的关系.心血管病学进展.2007,28(2)：208-211.
[36]Manabu Kashiwagi, Atsushi Tanaka, Hironori Kitabata, et al. Relationship Between Coronary Arterial Remodeling, Fibrous Cap Thickness and High-Sensitivity C-Reactive Protein Levels in Patients With Acute Coronary Syndrome. Circ J.2009,73:1291-1295.
[37]Bonnet J, McPherson R, Tedgui A,et al. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease:results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther.2008 Dec;30(12):2298-313.
[1]孔灵芝,胡盛寿.中国心血管病报告2006[M].北京：中国大百科全书出版社,2008：69-70.
[2]Rosamond W, Flegal K, Friday G, et al. Heart Disease and Stroke Statistics—2007 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation.2007;达式 115(5):69-171.
[3]Helen Y. L. Catherine E. C. Teisha A. R. Use of Secondary Prevention Drug Therapy in Patients With Acute Coronary Syndrome After Hospital Discharge. J Manag Care Pharm.2008;14(3):271-80.
[4]张代民,刘志华.他汀类药物在治疗心血管疾病中的多重效应.国际心血管病杂志.2008,35(1)：42-45.
[5]秦晋梅,李建军.他汀类药物的抗炎作用.中国动脉硬化杂志.2004,12(3)：363-366.
[6]杨长卫,郭飞,孟兆兵等.急性冠脉综合征早期他汀类药物对血管内皮功能的保护作用.心血管病学进展.2008,29：24-29.
[7]Gresser U, Gathof BS.Atorvastatin:gold standard for prophylaxis of myocardial ischemia and stroke-comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.Eur J Med Res.2004 Jan 26;9(1):1-17.
[8]Ray KK, Cannon CP, McCabe CH,et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes:results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol.2005 Oct 18;46(8):1405-10.
[9]Ray KK, Cannon CP. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol.2004 Dec;15(6):637-43.
[10]Fraley AE, Schwartz GG, Olsson AG et al. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes:Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering)trial.J Am Coll Cardiol.2009 Jun 9;53(23):2186-96.
[11]Ray KK, Cannon CP, Cairns R,et al. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes:results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol.2009 Mar;29(3):424-30.
[12]Schoenhagen P, Tuzcu EM, Apperson-Hansen C,et al. Determinants of arterial wall remodeling during lipid-lowering therapy:serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation.2006 Jun 20; 113(24): 2826-34.
[13]Bonnet J, McPherson R, Tedgui A,et al. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease:results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther.2008 Dec;30(12):2298-313.
[14]Lewandowski M, Kornacewicz-Jach Z, Millo B,et al. The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value. Cardiol J.2008;15(4):357-64.
[15]Kanadasi M, Cayli M, Demirtas M et al. The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol. Heart Vessels.2006 Sep;21(5):291-7. Epub 2006 Sep 29.
[16]Stefanadis C, Toutouzas K, Tsiamis E, Relation between local temperature and C-reactive protein levels in patients with coronary artery disease:effects of atorvastatin treatment. Atherosclerosis.2007 Jun;192(2):396-400.
[17]王岚峰,吴双,关秀茹,等.脑钠素与急性心肌梗死预后关系的临床研究[J].中华心血管病杂志,2005,33：234-237.
[18]张华,王泰蓉,陈华,等.三种标志物联合检测在急性冠脉综合征的应用.标记免疫分析与临床.2006,13(4)：198-200.
[19]程翔,廖玉华,郑金娥等.不稳定心绞痛患者CD4+CD25+调节性T细胞检测及意义.中国分子心脏病学杂志.2006,6(1)：17-19.
[20]Hu Z, Li D, Hu Y, Yang K. Changes of CD4+CD25+ regulatory T cells in patients with acute coronary syndrome and the effects of atorvastatin. J Huazhong Univ Sci Technolog Med Sci.2007 Oct,27(5):524-7.
[21]Barderas MG, Tunon J, Darde VM, et al. Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome.Proteomics.2009 Apr;9(7):1982-93.
[22]费瑜,张文琪等.急性心肌梗死患者PTCA后血浆可溶性细胞黏附分子-1变化及阿托伐他汀对其影响.中国急救医学.2003,23(11)：806.
[23]李泽林,孙华保,宁丹霞,等.大剂量阿托伐他汀对急性冠状动脉综合征患者血清抗氧化能力的影响.中国动脉硬化杂志.2006,14(8)：701-704.
[24]林毅,陈新民,罗助荣,等.不同剂量阿托伐他汀对急性冠脉综合征患者炎症及血小板和纤溶活性的影响.中国全科医学.2007,10(13)：1060-1062.